Vertex (VRTX) PT Raised to $500 at TD Cowen

TD Cowen analyst Phil Nadeau raised the price target on Vertex (NASDAQ: VRTX) to $500.00 (from $450.00) while maintaining a Buy rating.

The analyst commented, "We are updating our model in conjunction with TD Cowen Biotech's Q2 earnings preview. Specifically, we are updating Q2 estimates to reflect the one-time IPR&D charge of ~$4.4B related to the Alpine acquisition. We are also increasing our DCF-based P.T. from $450 to $500 to reflect additional years of CF franchise commercial life. We continue to consider VRTX a core large cap biotech holding."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'